Price: $381.0200
$0.23
0.060%
|
Day's High:
| $381.28
| Week Perf:
| 0.23 %
|
Day's Low: |
$ 380.51 |
30 Day Perf: |
1.17 % |
Volume (M): |
20,612 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 7,853,660 |
52 Wk Avg: |
$0.00 |
Open: |
$380.78 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
17,417 |
Shares
Outstanding (Millions) |
46 |
Employees |
1,536 |
Revenues (TTM) (Millions $) |
1,074 |
Net Income (TTM) (Millions $) |
267 |
Cash Flow (TTM) (Millions $) |
-109 |
Capital Exp. (TTM) (Millions $) |
28 |
Abiomed Inc
Abiomed Inc. is a medical device company that develops and manufactures products designed to support and enhance the pumping function of the heart. The company's primary product is the Impella, a miniature heart pump that provides temporary circulatory support to the heart during certain high-risk procedures, such as heart transplants, angioplasties, and stent placements.
Abiomed was founded in 1981 and is headquartered in Danvers, Massachusetts, with additional locations in Germany, Japan, and Switzerland. Since its inception, the company has been focused on developing innovative medical devices that can improve patient outcomes and reduce healthcare costs.
The Impella heart pump is Abiomed's flagship product and is designed to provide a minimally invasive alternative to traditional heart surgery. The device is inserted through a small incision in the groin and threaded up to the heart, where it is used to support the weakened or damaged heart during the procedure. The Impella is the only FDA-approved temporary heart pump that can be used for certain high-risk patients who have advanced heart failure or are undergoing certain heart procedures.
The company also offers a range of other medical devices and products, including the Breethe OXY-1 System, a portable oxygenation and ventilation system for patients with acute respiratory failure. Additionally, Abiomed has developed a range of educational and training programs designed to help healthcare professionals learn about and effectively use their products.
Abiomed has a strong history of success, with continued growth and expansion over the years. In 2021, the company reported annual revenue of over $800 million and employed more than 1,500 people. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol ABMD.
The company is known for its focus on patient care and innovation, with a commitment to developing new technologies and products that can improve patient outcomes and reduce healthcare costs. Abiomed is dedicated to working with healthcare professionals and organizations to ensure that their products are being used safely and effectively, and that patients are receiving the best possible care.
Company Address: 22 CHERRY HILL DRIVE Danvers 1923 MA
Company Phone Number: 646-1400 Stock Exchange / Ticker: NASDAQ ABMD
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Co Diagnostics Inc
Co Diagnostics Inc Announces Strong Revenue Growth and Declining Inventories Salt Lake City, March 14, 2024 - Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company, has reported its financial results for the full year ended December 31, 2023. The company's revenue for the fourth quarter of 2023 showed a remarkable growth of 140.476% year on year, amounting to $3.37 million. However, they experienced a loss of $-0.50 per share during this period. In comparison to other companies in the Medical Equipment and Supplies sector, Co Diagnostics Inc exhibited higher revenue growth. While the overall sector saw a revenue growth of 6.78% in the fourth quarter of 2023 relative to the same period a year ago, Co Diagnostics Inc surpassed this with its substantial increase.
|
Nephros Inc
As a Wall Street journalist, it is important to analyze the financial performance of companies like Nephros Inc in order to provide valuable insights to investors. For the fiscal fourth quarter of 2023, Nephros Inc reported a loss of $0.06 per share, which was an improvement from the loss of $0.16 per share in the same period a year prior. However, compared to the previous financial reporting period, the company's loss per share increased from $0.02. Despite the mixed results in terms of earnings, Nephros Inc saw a significant increase in revenue, with a growth rate of 67.971% to $3.44 million from $2.05 million in the same period last year. The company also reported a net loss of $0.654 million for the fiscal fourth quarter of 2023, compared to a loss of $1.527 million in the same period a year ago. While Nephros Inc's stockpiles increased to $2.5 million, it is worth noting that this level remains below the previous year's level of $3.2 million. The build-up in accounts receivable is a positive sign of rising demand, with accounts receivable valued at $1.5 million, higher than in the preceding quarter. Looking at the full-year results for 2023, Nephros Inc reported revenue of $13.41 million and a net loss of $1.58 million. The company managed to decrease its loss per share to $0.15 from $0.73 in the previous fiscal year, while revenue surged by 34.39% from $9.98 million a year prior.
|
Non Invasive Monitoring Systems Inc
The Medical Equipment and Supplies sector has been closely monitoring the performance of Non Invasive Monitoring Systems Inc as it enters the second quarter of 2024. The company has reported an operating loss of $-0.04 million for the period of November to January 31, 2024, with no mention of revenue figures thus far. This lack of revenue has raised concerns among sector contributors who are looking for signs of growth and financial stability. The Chief Financial Officer of Non Invasive Monitoring Systems Inc is actively pursuing various business strategies in an effort to expand the company's product line and increase profitability. However, the company continues to struggle, reporting a net loss of $-0.054 million for the same period. This represents an increase from the net loss of $-0.048 million reported during the similar period a year ago.
|
Anika Therapeutics Inc
In the dynamic world of the stock market, it is crucial for investors to stay informed about the financial performance and significant developments of companies. Anika Therapeutics Inc., a global joint preservation company in early intervention orthopedics, recently reported its financial results for the October to December 31, 2023, financial period. This article will highlight key observations from the company's financial report and analyze the impact of stock inducement grants on its current share structure and stock price. Financial Performance Overview: During the October to December 2023 financial period, Anika Therapeutics Inc. witnessed a significant increase in revenue, reaching $43.25 million, representing a growth of 9.151% year-on-year. In comparison to its contemporaries in the Medical Equipment and Supplies sector, Anika Therapeutics Inc.'s top-line growth outpaced the industry average, highlighting its strong market position.
|
Cytosorbents Corporation
CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies, has reported its financial performance for the fiscal period between October and December 31, 2023. While the company faced some challenges during this period, it also made significant progress and achieved notable accomplishments in the medical equipment and supplies sector. Financial Performance Summary During the mentioned fiscal span, Cytosorbents Corporation experienced a widening of diminishing returns, with a decrease of $0.12 per share compared to $0.02 a year ago. However, the company managed to improve its EPS from -$0.21 per share in the previous reporting season. Revenue declined by 15.714% to $7.91 million from $9.39 million in the same reporting season a year ago. Sequentially, revenue also deteriorated by 8.04% from $8.61 million.
|
Per Share |
Current |
Earnings (TTM) |
5.81 $ |
Revenues (TTM) |
23.5 $
|
Cash Flow (TTM) |
- |
Cash |
3.99 $
|
Book Value |
33.69 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
5.81 $
|
Revenues (TTM) |
23.5 $ |
Cash Flow (TTM) |
- |
Cash |
3.99 $
|
Book Value |
33.69 $ |
Dividend (TTM) |
0 $ |
|
|
|
|